Close
Digital Health & Ai Innovation summit 2026
Medical Taiwan 2026

Predictmedix AI Expands Diabetes Screening Solution in India

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Philips AI DeviceGuide Gets FDA Approval...

Regulatory clearance has been secured by Philips from the...

GE HealthCare Drives Cardio-Oncology Care in...

GE HealthCare has taken on the role of lead...

Medtronic ViaVerte Deal Expands Nerve Ablation...

Medtronic has entered into a distribution agreement with Merit...

Predictmedix AI has broadened its diagnostic capabilities within India by introducing a pioneering, non-invasive screening solution for diabetes.

Predictmedix AI product suite consists of the capability to identify initial indications of diabetes in individuals through the analysis of inconspicuous biological markers. These markers, typically overlooked by conventional methods, have now become accessible to Predictmedix’s advanced AI technology.

The new AI-powered diabetes non-invasive screening solution holds the potential to revolutionise public health by transforming the way we detect and intervene in cases of diabetes. The new initiative driven by AI is focused on reshaping the existing methods used for the early identification and intervention of a commonly prevalent chronic ailment.

The recently introduced non-invasive diabetes screening solution utilises sophisticated AI algorithms to examine a comprehensive range of relevant information. This includes the analysis of blood flow patterns to track changes in volumetric blood circulation, which are indicative of fluctuations in blood sugar levels.

By leveraging the capabilities of AI to identify potential cases in their early stages, makes a substantial contribution to the well-being of individuals and the broader community.

 

MEDICAL FAIR ASIA 2026

Latest stories

Related stories

Philips AI DeviceGuide Gets FDA Approval for Cardiac Use

Regulatory clearance has been secured by Philips from the...

GE HealthCare Drives Cardio-Oncology Care in EU COMPASS

GE HealthCare has taken on the role of lead...

Medtronic ViaVerte Deal Expands Nerve Ablation Portfolio

Medtronic has entered into a distribution agreement with Merit...

Abbott Scales Diagnostics with Exact Sciences Acquisition

Abbott has finalized the Exact Sciences acquisition, marking the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »